uniQure Gene Therapy Leadership January 2024

uniQure presents corporate strategy and pipeline progress in gene therapy, focusing on AMT-130 development for Huntington's disease treatment. The presentation outlines clinical trial data, biomarker utility for target engagement, and regulatory pathway advancement in the U.S. and Europe.